

**Impact of subject- and methodology-related factors on the
reproducibility of brachial artery flow-mediated vasodilation:
analysis of 672 individual repeated measurements**

**ANKE C.C.M VAN MIL, MSc. ^{A,B,C}, ARNO GREYLING, MSc. ^{A,D}, PETER L. ZOCK, PhD.
^{C,D}, MARIANNE J.M. GELEIJNSE, PROF. ^E, MARIA T. HOPMAN, M.D. ^{A,E}, RONALD P.
MENSINK, PROF. ^{F,C}, KOEN D. REESINK, PhD. ^G, DANIEL J. GREEN, PROF. ^{B,H}, LORENZO
GHIADONI, PROF. ^I, DICK H. THIJSSEN, PROF. ^{A,B}.**

^{A)} Department of Physiology, Radboudumc, Nijmegen, The Netherlands

^{B)} Research institute for Sport and Exercise Sciences, Liverpool John Moores University,
Liverpool, United Kingdom

^{C)} Top Institute for Food and Nutrition (TIFN), Wageningen, The Netherlands

^{D)} Unilever R&D Vlaardingen, Vlaardingen, The Netherlands

^{E)} Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands.

^{F)} Department of Human Biology, Maastricht University Medical Centre, Maastricht, The
Netherlands

^{G)} Department of Biomedical Engineering, Maastricht University Medical Centre, Maastricht,
The Netherlands

^{H)} School of Sports Science, Exercise and Health, The University of Western Australia,
Nedlands, Australia

^{I)} University of Pisa, Pisa, Italy

Short title: Reproducibility of repeated measurements of FMD

TOTAL WORD COUNT: 5775

ABSTRACT WORD COUNT: 246

FIGURES: 2

TABLES: 2

SUPPLEMENTARY FILES: 1

Author for correspondence:

Prof. Dr. Dick Thijssen, Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Tom Reilly Building, Byrom Street L3 3AF, Liverpool, United Kingdom
Email: D.Thijssen@ljmu.ac.uk, Tel: +441519046264

SOURCES OF FUNDING

Ms Anke van Mil is financially supported by a Top Institute for Food and Nutrition-grant.
Dr. Dick Thijssen is financially supported by the Netherlands Heart Foundation (E Dekker-stipend, 2009T064). Professor Green receives Fellowship and grant funding from the National Heart Foundation of Australia (APP1045204).

DISCLOSURES

AG and PLZ are employed by Unilever R&D Vlaardingen B.V. No conflicts of interest, financial or otherwise, are declared by the remaining author(s).

ABSTRACT

Objectives. Brachial artery flow-mediated dilation is a popular technique to examine endothelial function in humans. Identifying subject- and methodological factors related to variation in flow-mediated dilation is important to improve measurement accuracy and applicability.

Methods. Subject- and methodology-related parameters were collected in 672 subjects from 8 affiliated centres world-wide who underwent repeated measures of flow-mediated dilation. All centres adopted contemporary expert-consensus guidelines for flow-mediated dilation assessment. After calculating the coefficient of variation (%) of the flow-mediated dilation for each individual, we constructed quartiles (n=168 per quartile). Based on 2 regression models (1.Subject-related factors, 2.Methodology-related factors), statistically significant components of these two models were added to a final regression model (calculated as β -coefficient and R^2). This allowed us to identify factors that independently contributed to the variation in flow-mediated dilation%.

Results. Median coefficient of variation was 17.5%, with healthy volunteers demonstrating a coefficient of variation of 9.3%. Regression models revealed age ($\beta=0.248$, $P<0.001$), hypertension ($\beta=0.104$, $P<0.001$), dyslipidemia ($\beta=0.331$, $P<0.001$), time between measurements ($\beta=0.318$, $P<0.001$), lab experience ($\beta=-0.133$, $P<0.001$) and baseline flow-mediated dilation% ($\beta=0.082$, $P<0.05$) as contributors to the coefficient of variation. After including all significant factors in the final model, we found that time between measurements, hypertension, baseline flow-mediated dilation%, and lab experience with flow-mediated dilation independently predicted brachial artery variability (total $R^2=0.202$).

Conclusions. Whilst flow-mediated dilation% showed good reproducibility, larger variation was observed in conditions with longer time between measurements, hypertension, less experience and lower baseline flow-mediated dilation%. Accounting for these factors may improve flow-mediated dilation% variability.

73 **KEYWORDS:** Endothelial function, flow-mediated dilation, reproducibility,
74 ultrasonography, Doppler

75

76

INTRODUCTION

Cardiovascular disease remains the world's leading cause of morbidity and mortality. Previous studies have provided convincing evidence that endothelial dysfunction is an early manifestation of cardiovascular disease [1, 2], contributing to development and/or acceleration of the atherosclerotic process. Based on the detrimental role of endothelial dysfunction in this common disease process, studies have attempted to develop and validate (non-invasive) methods and biomarkers to assess endothelial function in humans. The conceptual idea is that identification of endothelial dysfunction, in symptomatic as well as asymptomatic subjects, is related to increased risk for future development of cardiovascular events [3, 4].

A frequently-used, non-invasive technique to examine endothelial function in humans *in vivo* is flow-mediated dilation (FMD) [5]. This measurement adopts high resolution ultrasonography to measure the conduit artery diameter dilatation in response to marked elevation in blood flow (and therefore shear stress) after a 5-minute period of distal limb ischemia [6]. Studies have provided evidence that the FMD-response is endothelium-dependent [7] and largely mediated by nitric oxide [8], an important and potent vasodilator and anti-atherogenic molecule. The measurement of endothelial function using FMD has become popular in clinically-orientated studies, likely because of its non-invasive nature, ability to predict cardiovascular events [4, 9-11] and correlation to coronary artery endothelial function [2, 12].

Despite its valid conceptual basis, a number of factors influence the variability of FMD [13, 14]. Previous studies found that FMD is influenced by lifestyle factors (e.g. smoking, physical activity), methodology (e.g. cuff placement, duration of ischemia), intake of food and

beverages, hormonal changes, and method of analysis [8, 11]. Although many of these factors are currently being controlled for through adopting expert-consensus guidelines [11, 15], variation in FMD remains. These sources of variation may be subject-and/or methodology-dependent, but this has not yet been systematically studied. Identification of such factors will contribute to the control of measurement error, which will help to appropriately power studies and aid in the construction of rigorous and standardized guidelines [11, 16].

The purpose of this study was to identify subject- and methodology-related factors that contribute to FMD variation in humans. To this end, we combined data from previous studies (from 8 research centres) that performed repeated measurements within-subjects of brachial artery FMD in a total of 672 individuals. All included studies were performed according to expert-consensus guidelines [11]. Subsequently, we assessed subject- and methodology-related factors that contributed to brachial artery FMD variability.

METHODS

Study population

The International Working Group on Flow-Mediated Dilation (IWG-FMD) originates from eight different research groups in four different countries. All groups provided written consent to contribute their data. We compiled subject-level data from all participating research centres (see supplementary list), including a total of 19 different studies. All affiliated researchers provided details on methodology of included studies in a specifically designed questionnaire. These details were cross-checked with earlier published and/or unpublished data. All centres received an outline of the datasheet, to enhance sufficient and complete data collection. A total of 84 parameters were explored. Data from a total of 672 individuals with measurement

of the brachial artery FMD, assessed on at least two separate occasions, obtained by B-mode ultrasound systems were available for data analyses. When studies included more than one repeated measurement, only the first and second measurement were included prior to statistical analyses. All subsequent repeated measurements were rejected, to prevent distortion included parameters.

Brachial artery flow mediated dilation measurements: methodological considerations

We included data from participants whose FMD data were collected on 2 separate occasions without an intervention between both measurements. These measurements were limited to the brachial artery (measurements of e.g. the radial-, femoral or popliteal arteries were excluded), in either the right or left arm (consistent for both measurements). To examine brachial artery FMD, participants extend the scanned arm following a short (10-15 minutes) resting period in the supine position. A rapid inflation and deflation pneumatic cuff was positioned on the forearm of the imaged arm distal to the olecranon process to provide a stimulus of forearm ischemia [11, 15]. With an ultrasound system, B-mode images of the brachial artery in the distal third of the upper arm (above the antecubital fossa in the longitudinal plane) were made. When an optimal image was obtained, the ultrasound probe was held stable (manually or by using a clamp) and ultrasound parameters were set to optimise the longitudinal B-mode image. At least one minute of baseline diameter was recorded, after which the pneumatic cuff was inflated to at least 50 mmHg above systolic pressure to occlude arterial inflow for a standardised length of time (i.e. standardised time of 5 minutes of occlusion). Subsequent cuff deflation induced a brief high-flow (hyperaemic) state that increased wall-shear stress at the brachial artery, causing it to dilate. To assess flow velocity, a mid-artery pulsed Doppler signal was obtained during the protocol [11, 15]. Whilst all study centres used slightly

different protocols to collect the repeated FMD measurements, all followed the above described expert-consensus guidelines.

Different types of ultrasound systems were used across the different centres, including; TerasonT3000 (Terason, Aloka, United Kingdom; 10-MHz multifrequency linear array transducer, n=136), Sonos 5500 (Hewlett-Packard, 7.5-MHz linear array transducer, n=20), ESAOTEMyLab25 (ESAOTE, Florence, Italy; 10-MHz linear array transducer, n=54), ESAOTE Picus Just 4D (ESAOTE, Maastricht, the Netherlands, 7.5-MHz linear array transducer, n=60), ESAOTE MyLabTM70 (ESAOTE, Maastricht, the Netherlands; 7.5-MHz linear array transducer, n=51), VIVID E9 (VIVID E9, General Electric, Waukesha, WI, USA, 15-MHz linear array transducer, n=109), AU5 Armonic system (ESAOTE, Florence, Italy; 7.0-MHz linear array transducer, n=136). One included study is a multi-centre study consisting of 7 sub-studies, which used a range of devices (ESAOTE, Philips, Siemens and General Electric, 7.5-10 MHz linear array transducer, n=110).

All studies used (semi)automatic analysis software. However, different software was used across the centres:(1) Custom made MyFMD software, V2012.2, Prof. A.P.G. Hoeks, Department of Biomedical Engineering, Maastricht University, Maastricht, the Netherlands (n=130); (2) Custom made software [17], Pisa, Italy (n=135); (3) Custom made DICOM software for edge-detection (n=135) [18, 19]; and (4) FMD Studio, Cardiovascular Suite, ClinicalPhysiology, National ResearchCouncil, Pisa, Italy (n=272) [20, 21]. All centres collected continuous measurements of the diameter and recorded these (on either VCR or digitally) for post-study analyses. No study used fixed time points for diameter estimation.

Sources of variation

Our primary outcome parameter was the variation between both FMD measurements, for which we calculated the coefficient of variation (CV) for each individual's repeated measurements, calculated as $[(\text{sdFMD}/\text{meanFMD}) \times 100]$. Furthermore, we recorded FMD (%), baseline diameter (cm), maximal diameter (cm), and time between measurements (categorized in <24h, 1-7 days, 8-14 days, 2-4 weeks, or >4 weeks).

Measurement of subject-related factors. We included the following subject-related factors, that were all presented using a continuous scale; age (inclusion ≥ 18 years, range 18-82 years); weight (range 45-171 kg); height (range 1.55-1.94 m); body mass index (calculated as weight (kg)/ height²(m), range 17.6-55.8kg/m²); systolic- and diastolic blood pressure (in mmHg) and calculated mean arterial pressure [MAP, calculated as $(2 \times \text{diastolic pressure} + \text{systolic pressure}) / 3$, range 64-139 mmHg]; and blood-specific parameters (i.e. total cholesterol; high density lipoprotein, HDL; low density lipoprotein, LDL; triglycerides; glucose; all in mmol/L). All original parameters were rescaled to the same metric or most frequently used units (i.e. cholesterol and glucose values converted from mg/dL to mmol/L)[22].

We also presented subject-related factors using categorical scales: sex (male/female); presence of hypertension (conform current guidelines defined as: systolic pressure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mmHg, or using blood pressure-lowering drugs, yes/no); the presence of diabetes (type 1 or type 2); smoking status (yes/no/history of smoking); presence of dyslipidemia (yes/no, as specified by each contributing centre), and history and/or presence of cardiovascular disease (CVD).

Measurement of methodology-related parameters. All assessments followed the expert-consensus FMD guidelines, ensuring that the protocol involved cuff placement around the forearm, occlusion for 5-minutes and cuff inflation ≥ 50 mmHg above systolic pressure. Furthermore, we assessed the following factors; use of a probe holder (yes/no); lab experience (total number of peer-reviewed publications that included measurement of FMD from contributing principal investigator through a Pubmed-based search using the search term “[author] AND flow mediated dilation”); mention of the laboratory’s own reported coefficient of variation (mentioned as CV% reported); use of continuous and/or ECG-gated diameter recording; measurement of artery diameter across the cardiac cycle; and the time between measurements (<24h, 1-7 days, 8-14 days, 2-4 weeks, and >4 weeks). The Supplementary material provides details of the questionnaire used to assess these factors.

Missing values

Since missing data were present for all of the 82 individual parameters, we used multiple imputation chained equations to impute parameters. We performed this procedure with a maximum up to 30%, as previously described [23, 24]. Parameters for which 31% or more was data were missing, were excluded from analyses and are not further mentioned. A more detailed outline of the imputation model can be found in the Supplementary material.

Statistical analysis

All data are presented as N(%) or mean \pm standard deviation unless stated otherwise. The main outcome measure for the reproducibility of the FMD is the coefficient of variation (CV) calculated for the mean difference between both FMD measurements. All descriptive data were examined in the pooled dataset and in quartiles of variation in FMD (i.e. CV). Based on the CV, we qualified the reproducibility as excellent (0-10%), good (10-20%), moderate (20-

30%) or poor (>30%)[25]. In multiple linear regression analyses we used the (log transformed) FMD CV as the dependent variable to identify factors that independently contributed to the variability of the FMD measurement, using backward regression analysis. A total of 4 models were constructed; Model 1a - Subject-related factors (continuous scale), Model 1b-Subject-related factors (categorical scale, i.e. presence of hypertension), Model 2-Methodology-related factors, and Model 3-Significant factors from previous models 1a-1b-2. Details of all regression models are given in the Supplemental information. All statistical analyses were performed using the Statistical Package for Social Sciences, version 20.0 (SPSS, INC. Chicago, IL, USA).

RESULTS

A median CV of 17.5% was observed for the entire population of 672 subjects, whilst a median CV of 9.3% was observed for volunteers without CV risk factors (n=109). We observed substantial variation between subjects regarding the individual CV for the FMD% (Figure 1). When dividing subjects into 4 quartiles, we calculated the CV for each quartile (Mean CV 29.9 ± 46.5 , range 0.14-745.33; Median CV Quartile-1 3.25%; Quartile-2 11.74%; Quartile-3 24.76%; Quartile-4 61.03%). We found an excellent, good or moderate CV in 33% (n=221), 22% (n=147), and 14% (n=94) of the sample, respectively. A poor CV was observed in 31% of the cases (n=210).

Subject-related factors

Age, BMI, total cholesterol, and glucose levels showed a gradual increase across quartiles, with Q3 and Q4 (i.e. large variation in FMD) showing significantly higher values than Q1 (Table 1). Systolic, diastolic and mean blood pressure were highest in Q2-3, whilst this

difference was lost in Q4 (Table 1). When subject-related factors were presented using a categorical scale, hypertension and dyslipidemia had significant impact on the reproducibility of the FMD (presence of hypertension Q1 15.5%, Q2 30.4%, Q3 32.1% and Q4 21.4%, diabetes Q1 0%, Q2 0%, Q3 1.2% and Q4 0.6%, both $P<0.001$), but not sex, smoking status, diabetes mellitus and CVD.

Methodology-related factors

FMD% and baseline diameter were significantly different across quartiles of the CV (Table 2). Subject in Q4 had a lower FMD and a larger baseline diameter (Table 2). We found that all factors related to the practical performance of the FMD, except the use of a probe holder, were significantly different between quartiles (Table 2). Larger variation in CV FMD% (i.e. Q3-4) was associated with absence of ECG-gated recording, no measurement of the diameter across the cardiac cycle, longer time between tests, less experience of the research centre in FMD measurements, and absence of reporting the CV of the laboratory in manuscripts (Table 2).

Regression analyses

Model 1a – Subject-related factors (continuous). After including all subject-related factors that significantly differed across quartiles, this model showed an $R^2=0.087$ and adjusted $R^2=0.086$. We found that only age predicted variation in FMD%CV ($\beta=0.248$, ratio of 28.1%, CI[0.020-0.035], p -value <0.001).

Model 1b–Subject-related factors (categorical). Including all subject-related factors that differed across quartiles, we found an $R^2=0.112$ and adjusted $R^2=0.108$. We identified hypertension ($\beta=0.104$, ratio of 11%, CI[0.095-0.533], p -value 0.005), dyslipidemia ($\beta=0.331$,

ratio of 39.2%, CI [0.813-1.275], *p-value* <0.001) and sex (β =-0.069, ratio of -6.7%, CI [-0.390-0.010], *p-value* 0.063) as significant predictors for the reproducibility of the FMD%.

Model 2–Methodology-related factors. This model showed an R^2 =0.198 and adjusted R^2 =0.184 when including methodology-related factors that differed across quartiles. The model identified time between measurements (β =0.318, ratio of 37.5%, CI [0.179-0.298], *p-value* <0.001), FMD% at baseline (β =-0.124, ratio of -11.7%, CI [-0.098--0.021], *p-value* 0.002), baseline diameter (β =0.082, ratio of 8.6%, CI [0.007-0.270], *p-value* 0.039) and lab experience (β =-0.133, ratio of -12.4%, CI [-0.011--0.003], *p-value* 0.001) as significant contributors to the variation in FMD% CV.

Model 3 - Overall model

Factors identified by models 1a, 1b and 2 were included in the overall model which resulted in an R^2 =0.208 and adjusted R^2 =0.202. Backward linear regression analysis identified time between measurements (β =0.291, ratio of 33.8%, CI [0.156-0.273], *p-value* <0.001), hypertension (β =0.096, ratio of 10.1%, CI [0.068-0.501], *p-value* 0.010), baseline FMD% (β =-0.142, ratio of -13.3%, CI [-0.105--0.030], *p-value* <0.001) and lab experience (β =-0.131, ratio of -12.3%, CI [-0.012--0.003], *p-value* 0.001) as significant contributors to the variation in FMD% across 2 repeated measurements (Figure 2). Baseline diameter demonstrated a borderline significant association with FMD% reproducibility (β =0.070, ratio of 7.2%, CI [-0.015-0.242], *p-value* 0.084).

DISCUSSION

This study included 672 repeated measurement of the brachial artery FMD, involving data from different research centres and various populations. This allowed us to comprehensively explore factors contributing to the within-subject variability of brachial artery FMD%, when measured according contemporary guidelines [11]. We present the following observations. First, the majority of the measurements showed an excellent-to-good reproducibility. For asymptomatic subjects, the median CV was 9.3%. This demonstrates that FMD is a reproducible tool to assess endothelial function *in vivo*. Secondly, we also found substantial variation between individuals in the CV of FMD%. In particular, the presence of hypertension contributed to a larger variation in FMD%, independent of other factors. Third, we found that a poorer reproducibility of the FMD was associated with the presence of a lower baseline FMD%, a higher baseline brachial artery diameter, a longer time period between repeated measurements, and less experience of the laboratory with the FMD measurement. Taking these factors into consideration for sample size calculations in future studies will help to decrease chances of type II errors.

Subject-related factors

Several previous studies have explored and described reproducibility of brachial artery FMD and presented mixed results, ranging from an excellent to poor reproducibility [13, 26, 27]. The overall median CV% in our analysis of 17.5% in the whole study population, and 9.3% in subjects without CV risk/disease, are in line with findings of most previous studies that reported a good reproducibility [14, 16, 28-30]. An important strength of our analysis is the large number of repeated measurements, which allowed us to identify between-subject and – laboratory related factors contributing to the variation in brachial artery FMD% within an individual. Interestingly, we found that older age, dyslipidemia and presence of hypertension

were related to larger variation in FMD%. This suggests, in agreement with previous work [28], that reproducibility of the FMD may be lower in populations with clinical symptoms than in healthy, young subjects.

An explanation for the larger variation in clinical populations could be the presence of a lower baseline FMD% that is typically observed in older subjects [31] and in those with hypertension [32], CVD [33] or dyslipidemia [14]. Indeed, we found that baseline FMD% is a strong and independent predictor for larger variability. Therefore, baseline FMD% was added to the statistical model to explore its impact on variability in FMD% independent of older age, hypertension and dyslipidemia. Interestingly, in this model the impact of age and dyslipidemia disappeared, suggesting that the lower baseline FMD% in older subjects is at least partly responsible for the larger variation with increasing age. In contrast, the impact of hypertension remained significant, indicating that other factors play a role in the larger variation in repeated measurements of brachial artery FMD%. Possibly, this poorer reproducibility may relate to higher stiffness of the vessels in clinical populations, compared to healthy volunteers [34]. Craiem *et al.* also found that subjects with CVD, despite comparable baseline FMD% values, demonstrate a larger coefficient of variation compared to healthy controls [28].

Methodology-related factors

Identification of methodology-related factors that contribute to the variation in FMD is highly relevant because such factors can potentially be controlled for. Several previous studies have highlighted the importance of methodological factors, which formed the basis for the FMD expert consensus guidelines [11]. The present study identified time between measurements and lab experience as independent determinants of the variation in FMD%, with more time

between FMD measurement leading to a higher CV. Most studies that explored FMD reproducibility included fixed time points between measurements, which makes direct comparisons of the duration between testing difficult. Interestingly, Charakida *et al.* explored FMD reproducibility after a few hours, 2 day, 3 months and 9 month [35]. In agreement with our findings, this study also demonstrate a poorer CV with increased time between re-testing. In contrast, Sorensen *et al.* found no difference in reproducibility when FMD was repeated after 1-2 days, 1-2 weeks or 2-4 months [27]. However, this study did not apply FMD measurements according to current guidelines, which may have affected the results. Whilst longer time between repeated measures may be associated with increased variability due to purely methodological variation, it is also likely that true biological variability is greater under circumstances where the repeated measure is more distant in time.

Laboratories that provided data for this analysis adopted expert consensus guidelines to perform and analyse FMD. This makes it difficult to explore the importance, for reproducibility, of the individual aspects within these guidelines. Nonetheless, our analysis showed that laboratory experience with FMD measurements independently contributes to the variation in FMD measurement. More specifically, the greater the experience of a laboratory with the FMD technique, the smaller the variation between repeated FMD measurements. This somewhat self-evident finding is nonetheless important, as it should guide laboratories who adopt the technique in attaining the level of practice and experience required before robust measures can be assumed. Nonetheless, limited experience of FMD did not completely invalidate assessment: the subgroup of healthy subjects without CV risk/disease that showed a CV of $9.3 \pm 19\%$ (n=109) included data from both experienced and less experienced laboratories, demonstrating the feasibility of a low CV in FMD measurements. This is in accordance with previous multi-centre studies [16]. These data demonstrate the importance of

adherence to the expert-consensus guidelines in addition to *a priori practice and* experience with the FMD-technique.

Practical relevance. This study demonstrates that, in addition to adopting current guidelines, some factors should be considered that might affect the variation of the FMD. For example, larger FMD reproducibility is observed when the time between measurements increases and/or in the presence of hypertension, and low resting FMD%. These factors should be taken into consideration when performing a sample size calculation and in the design of the study. Furthermore, the data of this study also emphasise that, in addition to fair reproducibility of the FMD in less experienced laboratories, training and gaining more experience is likely to minimise measurement error of the FMD-technique.

Limitations. One limitation of our study is that it was not prospectively designed to address FMD reproducibility. This may have introduced some error, especially relating to controlling physical activity and/or dietary instructions for the time between testing. However, all data was collected as in a ‘real world’ study rather than being set-up as a reproducibility study. Therefore, our study possesses ecological validity and can be extrapolated to various research settings. Another limitation is that all data in our analysis derive from laboratories adopting current guidelines for FMD measurement. Therefore, we were unable to address the relative importance of individual aspects included in these guidelines. In addition, whilst all centres indicated they adhered to the expert-consensus guidelines, we have no specific data on the internal control of adherence and/or small variation within these guidelines between centres (e.g. differences in analysis software, ultrasound machines). Such differences may in part contribute to the inherent variability of the FMD.

In conclusion, we have shown in a large dataset of repeated measurements that the majority of FMD measurements show an excellent-to-moderate reproducibility. Despite adopting expert consensus guidelines, several subject and methodology-related factors have independent impact on the variation in FMD% between two measurements. These include the presence of hypertension, a lower resting FMD%, a larger baseline artery diameter, a longer time between subsequent measurements, and less laboratory experience with the measurement. Future studies should take these subject- and methodology-related factors into consideration to improve sample size calculation. Such procedures will importantly decrease variability of the FMD and, consequently, decrease chances for type II errors in studies that rely on FMD as their primary outcome parameter.

ACKNOWLEDGEMENTS

We thank all individual researchers that contributed to data collection at Radboud University Medical Center (Dr. Tim Schreuder, Drs. Joost Seeger, Dr. Constantijn Wouters), Liverpool John Moore's University (Dr. Helen Jones, Dr. Gurpreet Birk, Dr. Thomas Bailey), The University of Western Australia (Dr. Ceri Atkinson, Dr. Louise Naylor, Dr Howard Carter), University of Pisa (Dr. Rosa Maria Bruno), Maastricht University (CARIM; Dr. Frank van Bussel, Dr. Yvo Kusters, NUTRIM; Dr. Peter Joris), and Wageningen University (Dr. Lieke Gijssbers, Dr. James Dower). We thank Dr. Lian van Engelen for her valuable contribution to the set-up, performance and interpretation of the statistical analysis.

417 **REFERENCE LIST**

- 418 1. Deanfield, J.E., J.P. Halcox, and T.J. Rabelink, *Endothelial function and dysfunction: testing*
419 *and clinical relevance*. Circulation, 2007. **115**(10): p. 1285-95.
- 420 2. Takase, B., A. Uehata, T. Akima, T. Nagai, T. Nishioka, A. Hamabe, *et al.*, *Endothelium-*
421 *dependent flow-mediated vasodilation in coronary and brachial arteries in suspected*
422 *coronary artery disease*. Am J Cardiol, 1998. **82**(12): p. 1535-9, A7-8.
- 423 3. Green, D.J., E.A. Dawson, H.M. Groenewoud, H. Jones, and D.H. Thijssen, *Is flow-mediated*
424 *dilation nitric oxide mediated?: A meta-analysis*. Hypertension, 2014. **63**(2): p. 376-82.
- 425 4. Ras, R.T., M.T. Streppel, R. Draijer, and P.L. Zock, *Flow-mediated dilation and*
426 *cardiovascular risk prediction: a systematic review with meta-analysis*. Int J Cardiol, 2013.
427 **168**(1): p. 344-51.
- 428 5. Anderson, T.J., *Prognostic significance of brachial flow-mediated vasodilation*. Circulation,
429 2007. **115**(18): p. 2373-5.
- 430 6. Celermajer, D.S., K.E. Sorensen, V.M. Gooch, D.J. Spiegelhalter, O.I. Miller, I.D. Sullivan, *et*
431 *al.*, *Non-invasive detection of endothelial dysfunction in children and adults at risk of*
432 *atherosclerosis*. Lancet, 1992. **340**(8828): p. 1111-5.
- 433 7. Dawson, E.A., S. Rathore, N.T. Cable, D.J. Wright, J.L. Morris, and D.J. Green, *Impact of*
434 *introducer sheath coating on endothelial function in humans after transradial coronary*
435 *procedures*. Circ Cardiovasc Interv, 2010. **3**(2): p. 148-56.
- 436 8. Green, D.J., H. Jones, D. Thijssen, N.T. Cable, and G. Atkinson, *Flow-mediated dilation and*
437 *cardiovascular event prediction: does nitric oxide matter?* Hypertension, 2011. **57**(3): p. 363-
438 9.
- 439 9. Inaba, Y., J.A. Chen, and S.R. Bergmann, *Prediction of future cardiovascular outcomes by*
440 *flow-mediated vasodilatation of brachial artery: a meta-analysis*. Int J Cardiovasc Imaging,
441 2010. **26**(6): p. 631-40.
- 442 10. Vita, J.A. and J.F. Keaney, Jr., *Endothelial function: a barometer for cardiovascular risk?*
443 Circulation, 2002. **106**(6): p. 640-2.

11. Thijssen, D.H., M.A. Black, K.E. Pyke, J. Padilla, G. Atkinson, R.A. Harris, *et al.*, *Assessment of flow-mediated dilation in humans: a methodological and physiological guideline*. *Am J Physiol Heart Circ Physiol*, 2011. **300**(1): p. H2-12.
12. Anderson, T.J., A. Uehata, M.D. Gerhard, I.T. Meredith, S. Knab, D. Delagrang, *et al.*, *Close relation of endothelial function in the human coronary and peripheral circulations*. *J Am Coll Cardiol*, 1995. **26**(5): p. 1235-41.
13. De Roos, N.M., M.L. Bots, E.G. Schouten, and M.B. Katan, *Within-subject variability of flow-mediated vasodilation of the brachial artery in healthy men and women: implications for experimental studies*. *Ultrasound in Medicine & Biology*, 2003. **29**(3): p. 401-406.
14. Donald, A.E., J.P. Halcox, M. Charakida, C. Storry, S.M. Wallace, T.J. Cole, *et al.*, *Methodological approaches to optimize reproducibility and power in clinical studies of flow-mediated dilation*. *J Am Coll Cardiol*, 2008. **51**(20): p. 1959-64.
15. Corretti, M.C., T.J. Anderson, E.J. Benjamin, D. Celermajer, F. Charbonneau, M.A. Creager, *et al.*, *Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force*. *J Am Coll Cardiol*, 2002. **39**(2): p. 257-65.
16. Ghiadoni, L., F. Fata, M. Salvetti, C. Cordiano, A. Biggi, M. Puato, *et al.*, *Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study*. *J Hypertens*, 2012. **30**(7): p. 1399-405.
17. Beux, F., S. Carmassi, M.V. Salvetti, L. Ghiadoni, Y. Huang, S. Taddei, *et al.*, *Automatic evaluation of arterial diameter variation from vascular echographic images*. *Ultrasound Med Biol*, 2001. **27**(12): p. 1621-9.
18. Black, M.A., N.T. Cable, D.H. Thijssen, and D.J. Green, *Importance of measuring the time course of flow-mediated dilatation in humans*. *Hypertension*, 2008. **51**(2): p. 203-10.
19. Woodman, R.J., D.A. Playford, G.F. Watts, C. Cheetham, C. Reed, R.R. Taylor, *et al.*, *Improved analysis of brachial artery ultrasound using a novel edge-detection software system*. *J Appl Physiol* (1985), 2001. **91**(2): p. 929-37.

20. Gemignani, V., E. Bianchini, F. Faita, C. Giannarelli, Y. Plantinga, L. Ghiadoni, *et al.*, *Ultrasound measurement of the brachial artery flow-mediated dilation without ECG gating*. *Ultrasound Med Biol*, 2008. **34**(3): p. 385-91.
21. Gemignani, V., F. Faita, L. Ghiadoni, E. Poggianti, and M. Demi, *A system for real-time measurement of the brachial artery diameter in B-mode ultrasound images*. *IEEE Trans Med Imaging*, 2007. **26**(3): p. 393-404.
22. Erasmus, M.C., *Conversiefactoren* A.K. Chemie, Editor 2010.
23. Engelen, L., I. Ferreira, C.D. Stehouwer, P. Boutouyrie, S. Laurent, and C. Reference Values for Arterial Measurements, *Reference intervals for common carotid intima-media thickness measured with echotracking: relation with risk factors*. *Eur Heart J*, 2013. **34**(30): p. 2368-80.
24. Sterne, J.A., I.R. White, J.B. Carlin, M. Spratt, P. Royston, M.G. Kenward, *et al.*, *Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls*. *BMJ*, 2009. **338**: p. b2393.
25. Thijssen, D.H., M.W. Bleeker, P. Smits, and M.T. Hopman, *Reproducibility of blood flow and post-occlusive reactive hyperaemia as measured by venous occlusion plethysmography*. *Clin Sci (Lond)*, 2005. **108**(2): p. 151-7.
26. Hardie, K.L., S. Kinlay, D.B. Hardy, J. Wlodarczyk, J.S. Silberberg, and P.J. Fletcher, *Reproducibility of brachial ultrasonography and flow-mediated dilatation (FMD) for assessing endothelial function*. *Aust N Z J Med*, 1997. **27**(6): p. 649-52.
27. Sorensen, K.E., D.S. Celermajer, D.J. Spiegelhalter, D. Georgakopoulos, J. Robinson, O. Thomas, *et al.*, *Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility*. *Br Heart J*, 1995. **74**(3): p. 247-53.
28. Craiem, D., G. Chironi, J. Gariepy, J. Miranda-Lacet, J. Levenson, and A. Simon, *New monitoring software for larger clinical application of brachial artery flow-mediated vasodilatation measurements*. *J Hypertens*, 2007. **25**(1): p. 133-40.
29. Donald, A.E., M. Charakida, T.J. Cole, P. Friberg, P.J. Chowienzyk, S.C. Millasseau, *et al.*, *Non-invasive assessment of endothelial function: which technique?* *J Am Coll Cardiol*, 2006. **48**(9): p. 1846-50.

30. Welsch, M.A., J.D. Allen, and J.P. Geaghan, *Stability and reproducibility of brachial artery flow-mediated dilation*. Med Sci Sports Exerc, 2002. **34**(6): p. 960-5.
31. Herrington, D.M., L. Fan, M. Drum, W.A. Riley, B.E. Pusser, J.R. Crouse, *et al.*, *Brachial flow-mediated vasodilator responses in population-based research: methods, reproducibility and effects of age, gender and baseline diameter*. J Cardiovasc Risk, 2001. **8**(5): p. 319-28.
32. Simova, I., A. Nossikoff, and S. Denchev, *Interobserver and intraobserver variability of flow-mediated vasodilatation of the brachial artery*. Echocardiography, 2008. **25**(1): p. 77-83.
33. Onkelinx, S., V. Cornelissen, K. Goetschalckx, T. Thomaes, P. Verhamme, and L. Vanhees, *Reproducibility of different methods to measure the endothelial function*. Vasc Med, 2012. **17**(2): p. 79-84.
34. Witte, D.R., Y. van der Graaf, D.E. Grobbee, M.L. Bots, and S.S. Group, *Measurement of flow-mediated dilatation of the brachial artery is affected by local elastic vessel wall properties in high-risk patients*. Atherosclerosis, 2005. **182**(2): p. 323-30.
35. Charakida, M., E. de Groot, S.P. Loukogeorgakis, T. Khan, T. Luscher, J.J. Kastelein, *et al.*, *Variability and reproducibility of flow-mediated dilatation in a multicentre clinical trial*. Eur Heart J, 2013. **34**(45): p. 3501-7.

517 **FIGURE LEGENDS**518 **Figure 1. Individual reproducibility in Brachial artery FMD**

519 Data of all subjects (n=672) relating to the individual reproducibility of the brachial artery

520 FMD across 2 repeated measurements.

521

522 **Figure 2. Regression analysis**523 Plot for regression coefficient β for the coefficient of variation (CV) of the flow mediated

524 dilation (FMD). * implies a statistical significant contribution in final model.

525

526

527 **TABLES**528 **Table 1. Subject-related factors**

Continuous scale	Pooled {29.9±46.5}	Quartile 1 {3.25%}	Quartile 2 {11.74%}	Quartile 3 {24.76%}	Quartile 4 {61.03%}	P-value
Age (years)	46±17 (655)	40±16 163	42±15 164	46±16* 164	54±16* 164	<0.001
Sex (% male)	66 671	64 168	67 168	68 167	67 168	0.895
Weight (kg)	77.4±13.1 636	75.9±12.1 163	76.7±11.8 161	78.6±14.4 160	78.3±14.1 152	0.210
Height (cm)	1.75±0.1 637	1.76±0.1 163	1.76±0.1 161	1.75±0.1 160	1.75±0.1 152	0.657
BMI (kg/m)	25.3±3.7 657	24.6±3.4 164	24.9±3.3 165	25.8±4.2* 164	25.9±3.5* 164	0.003
Systolic BP (mmHg)	129±15 645	127±13 161	131±14* 163	130±16* 159	128±15 162	0.023
Diastolic BP (mmHg)	79±11 645	78±11 161	81±12* 163	79±12 159	76±11 162	<0.001
Mean BP (mmHg)	96±12 655	94±11 135	98±12* 165	96±13 163	94±11 164	0.002
Cholesterol (mmol/L)	5.3±1.0 544	5.1±1.0 135	5.2±1.0 134	5.4±1.0* 134	5.6±0.9* 141	<0.001

HDL (mmol/L)	1.4±0.4 508	1.4±0.3 127	1.4 ±0.3 126	1.4±0.3 124	1.4±0.4 131	0.414
LDL (mmol/L)	3.5±0.8 466	3.3±0.8 115	3.3±0.8 109	3.5±0.9* 112	3.7±0.8* 130	<0.001
Triglycerides (mmol/L)	1.4±1 529	1.3±0.8 129	1.4±1.3 130	1.4±0.9 130	1.3±0.8 140	0.924
Glucose (mmol/L)	5.1±0.7 466	5.0±0.7 132	5.0±0.9 132	5.0±0.7 114	5.4±0.7* 88	<0.001

529 Subject-related factors for whole group (n=672) and quartiles (of n=168 each) with median CV reported per quartile. Data are reported as mean
530 ± SD with total number of subjects available for analysis presented below in italic. P-value refers to an ANOVA. *Post-hoc significantly different
531 from Quartile 1 at P<0.05

532 **Table 2. Methodological-related factors**

Continuous scale	Pooled {29.9±46.5}	Quartile 1 {3.25%}	Quartile 2 {11.74%}	Quartile 3 {24.76%}	Quartile 4 {61.03%}	P-value
Baseline diameter (mm)	4.3±0.8 672	4.1±0.8 168	4.3±0.7* 168	4.4±0.8* 168	4.4±0.8* 168	<0.001
Maximal diameter (mm)	4.5±0.8 672	4.3±0.8 168	4.5±0.7* 168	4.6±0.9* 168	4.5±0.8* 168	<0.001
FMD (%)	5.4±3.0 672	6.1±2.8 168	5.8±2.4 168	5.7±2.8 168	4.1±3.6* 168	<0.001
Laboratory experience (papers per PI)	29.2±24.8 672	35.6±21.9 168	35.1±22.9 168	30.9±25.3* 168	15.4±23.6* 168	<0.001
CV reported (%)	16.8±9.5 612	14.7±6.9 155	14.6±6.7 160	16.5±9.5 158	22.2±12.4 139	<0.001
Categorical scale						
Analysis by laboratory	96 672	99 168	99 168	95* 168	92* 168	<0.001
ECG-gated recording	28 672	25 168	38* 168	35* 168	13* 168	<0.001
Cardiac cycle (%)	84 672	87 168	88 168	87 168	73* 168	<0.001
Probe holder (%)	80 672	77 168	79 168	77 168	86 168	0.110


Time: <24 hours (%)	53	69	69	52	21	<0.001
1-7 days (%)	6	6	9	6	4	
8-14 days (%)	7	5	5	10	8	
2-4 weeks (%)	9	9	6	8	11	
>4weeks (%)	25	11	11	24	56	
	<i>672</i>	<i>168</i>	<i>168</i>	<i>168</i>	<i>168</i>	

Methodological-related factors presented for whole group (n=672) and quartiles (n=168 each) with median CV reported per quartile. Data are reported as mean ± SD with the total number of subjects available for analysis presented below in italic. P-value refers to an ANOVA. *Post-hoc significantly different from Quartile 1 at P<0.05.



538

539



540